{"ticker": {"uuid": "ca68c8a2-725f-4a56-a3bf-cfc839500ac8", "symbol": "1276", "name": "Jiangsu Hengrui Pharmaceuticals Co.,Ltd", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMnIzeEQyMGViU3k1Q1Q1aE9qVVBndDdKbzVBbU1zSklicHVLcHo0cGJvOGhHZENESzVlNlAzbVRNdG9lWl9PSXRzV28teWJ2bGRLdzhGZUc3NE96aHhsd0c0bzdZek15REtYVy1oQkhxeUk1S09sTXNMN2hqSmk2c01iRjdFMnliTnJ3NEJMd1ZYWjFtM0FzaW5Vbk9ZTVFEN1F2OXpOUlpOc1dqZFg0SmJGNnIteXhVckE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Hengrui gets boost from fifth drug-licensing deal of year", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQT0M5Y1FvN1BHNHRzT29FbnhLZVJhUWJiMUwtdm9pR0M2Ykt4cEFiQmt0UVlZeUFkWmk1bDNHQU1NcHJ6cmhBdGxJUGxpZWxqc0h2ZVZEcEFRNHpzQ3hjTTA2S2xpWW1uVkp5Y1I4cVNLRVhrQVY5dVc0OUVlYm5idXFqWDRwa0FJMTVkMF9rODFRZ3dwaGplOVpsaVg0WlVYc0FNQXlRV25mVU04ZDF1UzZoMkU5cGNtYktud3ln0gG-AUFVX3lxTE5ZOVB3bHdaYlVNbjFKVjltRnJBWUtjR2lSR1FhcXZSTDI2YnE3WkJENlNZT1J3TDE0Qmt1di0wMHJHUzVKa2JZNVFnWDRnNE5oTGZHLTQycHdCRXp4Sjltdkh0b3llMm5hdVYyVlprWEh4eTFFblVDTGxOeGhuVGZpT2ZtbW45X3pNX2pJR24tM2dPUW95ZTBST2tCblpkeFBoNU01T1Q4aE1DUERRdDhCendkMWxsZEdSamVabHc?oc=5", "source_name": "South China Morning Post", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPY3BrTlpoYlVvQXdaQUI5bjVVZHJkMURtcXZ0LWZDR09ZSXJEc3RHLVdnVFJ5YmZxay1oc2xNOTRsOWRNTTNaLUZoejlHeFRxODJFQUZib2dua21NN05CeTRsODZuWTU2MFRXdXBqc3dRZWRFVzdBakVhcDg2V2trSGc1dHdDUkp6bHM5WXlIRzd1YlhUTmI4ZGd6LW9GRFYwU1E?oc=5", "source_name": "BioWorld News", "published_at": "2025-09-09T07:00:00+00:00", "published_display": "09 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fierce Pharma Asia\u2014GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMWxFZEMxVFhRMllSRWhKdzIyWkNVSlVpdG94cWhLODhLakpWeVJ3QWFNLUNPTjVqcTUyRXlOWXVMLWVGMkhVdzVlN1MyY2RCemwtM2ZMNkFqekVXcXJQVWFYWEJtMVdTMTVGSTVWazhIQ0pHUTlnekhWM1FERHVUUEpWNWo1dGxVUTVRTjk0Z3FPdmRHb3lHZ2doYmlPbFRldHpxR3IyalNYZHNXd2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1cta19lTmdVSkppd3h2MjRpd3BNZW82M0VqMU5QUGtvckpzak5ydE9hVE5sZnBOOUJTejQ5QjZtUG45NFNvNU9Dd0ZkVnNXZmJFcDdNbW1nSXVNU1Y3S2xiSHpodHdlZDFNTHdoTXYtRXRLU2FDTWNwbVpTZG1oRl9pS2o3eHU5c2ZTd0l3cjdTSnhGRkFqZUVpLVNxQ3h1MnlVV1h5eGI?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi7gFBVV95cUxOcHpvUEZYQ2E4VVRKbjhXTnVBMUw3ZHBYTlc5bzk0TGVHV0lYeFVtX28xU3ZoWHE2VDhINzh6NkRwZUhXUVlFYkNsb2EyT3JIcDE3RjBaQ2tqS2h6LWk2Y2E0M0lDYWFyaFBJN283VHJVMmQ1bFFLa3R3WTJGOUg5WjBKd1lZbTRLUHotOWVrbjZleHBCYmZRdlZVajEyb2hZdWl4QmxTMG82Um5KdW9TU2NSMTVtVHJvcW1BdkRpeHVLbWdYbVBxV0U5Njh5YXJGdlprMWtxdlJubFlCUzgyT09KMi1HZndiMHNlc1F30gHzAUFVX3lxTE5Cdkt5ekFjQl9WTTYwbUs4eGtSdVRlRzJGcWNsaUp1bjdxanZzRTNUUkNjeXpOM1lLbjVWR1RCMlM0M3FMTC1SaDk2RkhpbFhkSm00Q3F2SVVpTmZkM3dQWG9Va1V3bDc4WWY4N0p2NFpBVk9DSlVnUXhQbzZXUF9UeVNodFRQSlFDUFFEdUtLUDR6cVZuTFFoRmFGSERIZHhUSDFqU1NCNDhRSmdlSVozMHJvZEpEWjN3T01mZnJ3LWwyWkloVkJPQ2l6TERJenp6MWV6cEc0QlNRb1dkbE50VTl1YndqVHVvMFZmVjEtRW04NA?oc=5", "source_name": "ETPharma.com", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK, China's Jiangsu Hengrui strike $500 million drug-development deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5", "source_name": "Reuters", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui raises HKD9.8bn in HK\u2019s largest pharma IPO in 5 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9VRThrWERwUEJGTnMzSERyVUxMbzBSaHo5MGloVjUyTFpnM1pIX2NtenI4OXdrQWVKR1llcjkycTZZcGJMZ3ZFaFhDdGFOVk9aLTVsZ1NKTkI3UThFcllYcDktMUJPdE9qZHVfa0FBUWc?oc=5", "source_name": "Law.asia", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQR01VWktIR2toXzg2aF85S1VEVk5xOXVxM3k4VEVka01iaWRQVzZOSHF4aFVfVmdYcnpKMmVuY05rS3BkWUJrb05ORXM4SGpJeEVxMkt0S0h4S0VSTFkyMTYwVkxCVmNGSG5xd2NDLXdMZHZaNkpxT2pidHNiUkNkb25lamd0dGlELV9xTVo0RkRDUVZMWldQQ2JzWWkxSzdLOVRRMEJLMWpjYVhKb05QdzJ3UnA?oc=5", "source_name": "Cleary Gottlieb", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Chinese drugmaker Hengrui soars in Hong Kong trading debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOdlRMckRYWHVzUXBFUS1WU2dIUGpXcWZBc2s3YU90MW9tbTdUUFhtVW1aWEMwX0ttamNKZ2wybUZtQU5TWkFkZmRzVW4wZldFRm1sNjhOOTIzX1B4TTdQWjZGLUV1YUotdHV3Z3lHVjRWaWVYZ2JjSWo3NHYxQTAtME13cE5hbXJKLVVrZmh0emlUSkR1VEhXQWkzRmMxUVRz?oc=5", "source_name": "Fortune", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc1dhZldSbUNQQWdIdFRpaHc3RzM1N2xVOE4xNFZXU2psOWN0aHJkYVU0a1h1ZGplaGI3SDVUd0VpMDlSUm45UkhTRTZIY053a0N1SzBvaEphODRFZXVsaGxZWTFQNW1wVjBwcFNmNk9yRzc3bHgwUDdKcUdpeWhGa2prVi1OdnpydGFJc1VXcVl5MDhiNWUyc1ByV0ZRaGRTVmRhN1NSQ2NtYXhVX1JKRA?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui jumps 25% in solid Hong Kong trading debut", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Jiangsu Hengrui to raise $1.27 billion in Hong Kong listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcXhHLTNEY1VEQy1WLWg1NzJ4ZFRrVjdScDZMRUp4N1gtV1F4SmxrVXpHVVJZMXNfRGdhTGFDRTZXeXRHT3lnWFlBZ3BzWFFrV3BZSkxERmtXVDFVRDRxQjByclZxNHJ2Rk9lRC16QzV4eFVlZGZWMTR5TXR6UEYwc0Q5M01EQWVER0F0N3l5aFhMV2VaVXE0SGZyYWp4V1dMY0YxbUNhNFNwRzczLUszeVp0QlFtWE5ka3d4Z1BSMlpvMFdoU3owdTZBMW9MM0hvTFhXZ3U1NUJ5QQ?oc=5", "source_name": "Reuters", "published_at": "2025-05-21T07:00:00+00:00", "published_display": "21 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cleary, HSF leading on Jiangsu Hengrui\u2019s $1.3 bln Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQekU0ZWhheVlDZzBnRHZRY0x6czVKellQUTRmWlR2dTRFVWduUFZReG8tX0FCajI3TWhuQkFmV181Q2xnZWUyWVhGOGtwd1NwODdjdXFlNXFjR09CYWNBb2w0b2Q3aEo0ME9kc2VUZ1lDWkxPeGsxVEVNTXN1OTNFVzJRUDRKN3VEZmNCZ1c4Ynp1ZkpYUEs1Nk1TeU1TLWhGM0NHVGNndlhrQQ?oc=5", "source_name": "| Asian Legal Business", "published_at": "2025-05-16T07:00:00+00:00", "published_display": "16 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Jiangsu Hengrui Pharmaceuticals aims to raise up to nearly HK$10 billion in Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPQlFUaWVuMXl2RFlyWjJaQW5LbHFfQTB4cmVTc1BoUlRWa3k2N1lhR0l0Qk1Cc1RnWTFCZ2NQX25uX1oyN3Rmd1ZCeE1ocEc2Z01yd1RYSFJuQ0kyS3l1Z1AzQVBZb01EMHB0b25TQUwzN1VITzhiVVBNNDRpZWMweFRmdGJhQTZzNzZyd3pVdzhDSVJLQXYycVQtb1Fyd2FYbFJ6eU1BZW03Vk9wWVd4MF9pVTMtSW1Xb3B3ZFFsTHVRM0RkQXlFYmNDaDlrbHYtT1ZNcVYybGRFWXlWc2k4NEVWdw?oc=5", "source_name": "thestandard.com.hk", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Hengrui become a global pharmaceutical giant like Merck after its Hong Kong IPO?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-05-06T07:00:00+00:00", "published_display": "06 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui officially submitted its application to the Hong Kong Stock Exchange, starting the second step of its internationalization.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPM1dSSGNhaEVLYVA5WTRtXzF4bWVETU14dk82VjJzaHhES1IxdjJJV3JTUTlGcjNIUk90dVlSYzFpRG5PdzBmNzBDeVBQaGw4T0NSWVREWjhTaVctZlppNTJrNGJHT2Z2V3ZHaU9XOHhNVkVMcVRUXzB4VjFWZVlKXzEzOFRHMnJBUHNWYXlVWDB4QWdfQVFkRHJ6V29YTGhoNFpHZHpla1ktcVh1eVE?oc=5", "source_name": "Moomoo", "published_at": "2025-01-06T08:00:00+00:00", "published_display": "06 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxPMnIzeEQyMGViU3k1Q1Q1aE9qVVBndDdKbzVBbU1zSklicHVLcHo0cGJvOGhHZENESzVlNlAzbVRNdG9lWl9PSXRzV28teWJ2bGRLdzhGZUc3NE96aHhsd0c0bzdZek15REtYVy1oQkhxeUk1S09sTXNMN2hqSmk2c01iRjdFMnliTnJ3NEJMd1ZYWjFtM0FzaW5Vbk9ZTVFEN1F2OXpOUlpOc1dqZFg0SmJGNnIteXhVckE?oc=5", "source_name": "Investing.com", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Hengrui gets boost from fifth drug-licensing deal of year", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQT0M5Y1FvN1BHNHRzT29FbnhLZVJhUWJiMUwtdm9pR0M2Ykt4cEFiQmt0UVlZeUFkWmk1bDNHQU1NcHJ6cmhBdGxJUGxpZWxqc0h2ZVZEcEFRNHpzQ3hjTTA2S2xpWW1uVkp5Y1I4cVNLRVhrQVY5dVc0OUVlYm5idXFqWDRwa0FJMTVkMF9rODFRZ3dwaGplOVpsaVg0WlVYc0FNQXlRV25mVU04ZDF1UzZoMkU5cGNtYktud3ln0gG-AUFVX3lxTE5ZOVB3bHdaYlVNbjFKVjltRnJBWUtjR2lSR1FhcXZSTDI2YnE3WkJENlNZT1J3TDE0Qmt1di0wMHJHUzVKa2JZNVFnWDRnNE5oTGZHLTQycHdCRXp4Sjltdkh0b3llMm5hdVYyVlprWEh4eTFFblVDTGxOeGhuVGZpT2ZtbW45X3pNX2pJR24tM2dPUW95ZTBST2tCblpkeFBoNU01T1Q4aE1DUERRdDhCendkMWxsZEdSamVabHc?oc=5", "source_name": "South China Morning Post", "published_at": "2025-09-25T07:00:00+00:00", "published_display": "25 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPY3BrTlpoYlVvQXdaQUI5bjVVZHJkMURtcXZ0LWZDR09ZSXJEc3RHLVdnVFJ5YmZxay1oc2xNOTRsOWRNTTNaLUZoejlHeFRxODJFQUZib2dua21NN05CeTRsODZuWTU2MFRXdXBqc3dRZWRFVzdBakVhcDg2V2trSGc1dHdDUkp6bHM5WXlIRzd1YlhUTmI4ZGd6LW9GRFYwU1E?oc=5", "source_name": "BioWorld News", "published_at": "2025-09-09T07:00:00+00:00", "published_display": "09 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China\u2019s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-09-05T07:00:00+00:00", "published_display": "05 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Fierce Pharma Asia\u2014GSK's massive Hengrui deal; Takeda's revenue drop; Celltrion's major US plant buy", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxQMWxFZEMxVFhRMllSRWhKdzIyWkNVSlVpdG94cWhLODhLakpWeVJ3QWFNLUNPTjVqcTUyRXlOWXVMLWVGMkhVdzVlN1MyY2RCemwtM2ZMNkFqekVXcXJQVWFYWEJtMVdTMTVGSTVWazhIQ0pHUTlnekhWM1FERHVUUEpWNWo1dGxVUTVRTjk0Z3FPdmRHb3lHZ2doYmlPbFRldHpxR3IyalNYZHNXd2c?oc=5", "source_name": "Fierce Pharma", "published_at": "2025-08-01T07:00:00+00:00", "published_display": "01 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOY1cta19lTmdVSkppd3h2MjRpd3BNZW82M0VqMU5QUGtvckpzak5ydE9hVE5sZnBOOUJTejQ5QjZtUG45NFNvNU9Dd0ZkVnNXZmJFcDdNbW1nSXVNU1Y3S2xiSHpodHdlZDFNTHdoTXYtRXRLU2FDTWNwbVpTZG1oRl9pS2o3eHU5c2ZTd0l3cjdTSnhGRkFqZUVpLVNxQ3h1MnlVV1h5eGI?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui grants GSK global rights to drug portfolio in $500 million deal", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "ETPharma.com", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK, China's Jiangsu Hengrui strike $500 million drug-development deal", "summary": "", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxQUGpsODM0QnE0alFCOUc1YVp5dm9pT1ZmN1ZFcGJWeFAwSzRTaGtJODlVaEJJZlVFMGpQVWtpYnZEMFhoQTZkNDJHRDZ5VVhUcHNZLXJxOGNMMjNobTRKUXpXdlBwV01MY1RaVE5abEFBbnB1WjRRbG1WZldmOUxxT19UNWNjdEdUTFBUOEtjUF82bW9nR29MNG5CVm9Ya1pFcEVfUF93ZzhXQTNrZTR4dHVKYlhKRXEycEtRaW1QS2JBWkcySC1BWVBpMi0zR0pXLW9uSFFn?oc=5", "source_name": "Reuters", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GSK to pay Hengrui US$12.5 billion for global rights to 12 drug projects", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-07-28T07:00:00+00:00", "published_display": "28 Jul 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui raises HKD9.8bn in HK\u2019s largest pharma IPO in 5 years", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9VRThrWERwUEJGTnMzSERyVUxMbzBSaHo5MGloVjUyTFpnM1pIX2NtenI4OXdrQWVKR1llcjkycTZZcGJMZ3ZFaFhDdGFOVk9aLTVsZ1NKTkI3UThFcllYcDktMUJPdE9qZHVfa0FBUWc?oc=5", "source_name": "Law.asia", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui Pharmaceuticals in HK$9.9 Billion IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQR01VWktIR2toXzg2aF85S1VEVk5xOXVxM3k4VEVka01iaWRQVzZOSHF4aFVfVmdYcnpKMmVuY05rS3BkWUJrb05ORXM4SGpJeEVxMkt0S0h4S0VSTFkyMTYwVkxCVmNGSG5xd2NDLXdMZHZaNkpxT2pidHNiUkNkb25lamd0dGlELV9xTVo0RkRDUVZMWldQQ2JzWWkxSzdLOVRRMEJLMWpjYVhKb05QdzJ3UnA?oc=5", "source_name": "Cleary Gottlieb", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Chinese drugmaker Hengrui soars in Hong Kong trading debut", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxOdlRMckRYWHVzUXBFUS1WU2dIUGpXcWZBc2s3YU90MW9tbTdUUFhtVW1aWEMwX0ttamNKZ2wybUZtQU5TWkFkZmRzVW4wZldFRm1sNjhOOTIzX1B4TTdQWjZGLUV1YUotdHV3Z3lHVjRWaWVYZ2JjSWo3NHYxQTAtME13cE5hbXJKLVVrZmh0emlUSkR1VEhXQWkzRmMxUVRz?oc=5", "source_name": "Fortune", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Top Chinese Drugmaker Hengrui Set to Begin Hong Kong Trading", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxNc1dhZldSbUNQQWdIdFRpaHc3RzM1N2xVOE4xNFZXU2psOWN0aHJkYVU0a1h1ZGplaGI3SDVUd0VpMDlSUm45UkhTRTZIY053a0N1SzBvaEphODRFZXVsaGxZWTFQNW1wVjBwcFNmNk9yRzc3bHgwUDdKcUdpeWhGa2prVi1OdnpydGFJc1VXcVl5MDhiNWUyc1ByV0ZRaGRTVmRhN1NSQ2NtYXhVX1JKRA?oc=5", "source_name": "Bloomberg.com", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiangsu Hengrui jumps 25% in solid Hong Kong trading debut", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-05-23T07:00:00+00:00", "published_display": "23 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Jiangsu Hengrui to raise $1.27 billion in Hong Kong listing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxPcXhHLTNEY1VEQy1WLWg1NzJ4ZFRrVjdScDZMRUp4N1gtV1F4SmxrVXpHVVJZMXNfRGdhTGFDRTZXeXRHT3lnWFlBZ3BzWFFrV3BZSkxERmtXVDFVRDRxQjByclZxNHJ2Rk9lRC16QzV4eFVlZGZWMTR5TXR6UEYwc0Q5M01EQWVER0F0N3l5aFhMV2VaVXE0SGZyYWp4V1dMY0YxbUNhNFNwRzczLUszeVp0QlFtWE5ka3d4Z1BSMlpvMFdoU3owdTZBMW9MM0hvTFhXZ3U1NUJ5QQ?oc=5", "source_name": "Reuters", "published_at": "2025-05-21T07:00:00+00:00", "published_display": "21 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cleary, HSF leading on Jiangsu Hengrui\u2019s $1.3 bln Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQekU0ZWhheVlDZzBnRHZRY0x6czVKellQUTRmWlR2dTRFVWduUFZReG8tX0FCajI3TWhuQkFmV181Q2xnZWUyWVhGOGtwd1NwODdjdXFlNXFjR09CYWNBb2w0b2Q3aEo0ME9kc2VUZ1lDWkxPeGsxVEVNTXN1OTNFVzJRUDRKN3VEZmNCZ1c4Ynp1ZkpYUEs1Nk1TeU1TLWhGM0NHVGNndlhrQQ?oc=5", "source_name": "| Asian Legal Business", "published_at": "2025-05-16T07:00:00+00:00", "published_display": "16 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "China's Jiangsu Hengrui Pharmaceuticals aims to raise up to nearly HK$10 billion in Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxPQlFUaWVuMXl2RFlyWjJaQW5LbHFfQTB4cmVTc1BoUlRWa3k2N1lhR0l0Qk1Cc1RnWTFCZ2NQX25uX1oyN3Rmd1ZCeE1ocEc2Z01yd1RYSFJuQ0kyS3l1Z1AzQVBZb01EMHB0b25TQUwzN1VITzhiVVBNNDRpZWMweFRmdGJhQTZzNzZyd3pVdzhDSVJLQXYycVQtb1Fyd2FYbFJ6eU1BZW03Vk9wWVd4MF9pVTMtSW1Xb3B3ZFFsTHVRM0RkQXlFYmNDaDlrbHYtT1ZNcVYybGRFWXlWc2k4NEVWdw?oc=5", "source_name": "thestandard.com.hk", "published_at": "2025-05-15T07:00:00+00:00", "published_display": "15 May 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can Hengrui become a global pharmaceutical giant like Merck after its Hong Kong IPO?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "South China Morning Post", "published_at": "2025-05-06T07:00:00+00:00", "published_display": "06 May 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hengrui officially submitted its application to the Hong Kong Stock Exchange, starting the second step of its internationalization.", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxPM1dSSGNhaEVLYVA5WTRtXzF4bWVETU14dk82VjJzaHhES1IxdjJJV3JTUTlGcjNIUk90dVlSYzFpRG5PdzBmNzBDeVBQaGw4T0NSWVREWjhTaVctZlppNTJrNGJHT2Z2V3ZHaU9XOHhNVkVMcVRUXzB4VjFWZVlKXzEzOFRHMnJBUHNWYXlVWDB4QWdfQVFkRHJ6V29YTGhoNFpHZHpla1ktcVh1eVE?oc=5", "source_name": "Moomoo", "published_at": "2025-01-06T08:00:00+00:00", "published_display": "06 Jan 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 75, "total_relevant": 20, "sentiment_summary": {"positive": 5, "negative": 0, "neutral": 15, "score": 54, "total": 20, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 6.75, "count": 11}, {"event": "deals", "label": "Deals and strategy", "weight": 4.55, "count": 7}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 5, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 59.25, "latest_week": "2026-07-10", "one_week_move": -1.1, "four_week_move": 7.4, "twelve_week_move": -10.5, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.911142, "market_dynamics_buy_signal": false, "relative_strength": -10.661706, "fair_value_gap": -14.1, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 44.7682, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.1% over one week, +7.4% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 62, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "South China Morning Post", "count": 5}, {"label": "Bloomberg.com", "count": 2}, {"label": "Reuters", "count": 2}, {"label": "Investing.com", "count": 1}, {"label": "ad-hoc-news.de", "count": 1}, {"label": "BioWorld News", "count": 1}, {"label": "Fierce Pharma", "count": 1}, {"label": "ETPharma.com", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 20}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 11}, {"label": "Deals and strategy", "count": 7}, {"label": "Capital return", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "20", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-1.1% over one week, +7.4% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Positive", "tone": "positive", "text": "Hengrui Pharma shares surge on $1 bln Bristol-Myers partnership"}], "updated_at": "2026-07-18T02:55:23.546455+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}